107335 20210913154736.0 doi 10.1039/d0bm01013h sideral 121249 ART-2020-121249 eng Rodrigo, M.J. Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model 2020 Intravitreal administration is widely used in ophthalmological practice to maintain therapeutic drug levels near the neuroretina and because drug delivery systems are necessary to avoid reinjections and sight-threatening side effects. However, currently there is no intravitreal treatment for glaucoma. The brimonidine-LAPONITE® formulation was created with the aim of treating glaucoma for extended periods with a single intravitreal injection. Glaucoma was induced by producing ocular hypertension in two rat cohorts: [BRI-LAP] and [non-bri], with and without treatment, respectively. Eyes treated with brimonidine-LAPONITE® showed lower ocular pressure levels up to week 8 (p < 0.001), functional neuroprotection explored by scotopic and photopic negative response electroretinography (p = 0.042), and structural protection of the retina, retinal nerve fibre layer and ganglion cell layer (p = 0.038), especially on the superior-inferior axis explored by optical coherence tomography, which was corroborated by a higher retinal ganglion cell count (p = 0.040) using immunohistochemistry (Brn3a antibody) up to the end of the study (week 24). Furthermore, delayed neuroprotection was detected in the contralateral eye. Brimonidine was detected in treated rat eyes for up to 6 months. Brimonidine-LAPONITE® seems to be a potential sustained-delivery intravitreal drug for glaucoma treatment. Access copy available to the general public Unrestricted info:eu-repo/grantAgreement/ES/ISCIII/M17-00213 info:eu-repo/grantAgreement/ES/ISCIII/PI17-01726 info:eu-repo/grantAgreement/ES/ISCIII/PI17-01946 info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 6.843 2020 MATERIALS SCIENCE, BIOMATERIALS 8 / 40 = 0.2 2020 Q1 T1 1.421 2020 Materials Science (miscellaneous) 2020 Q1 Biomedical Engineering 2020 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion Cardiel, M.J. Universidad de Zaragoza (orcid)0000-0002-7914-4685 Fraile, J.M. Universidad de Zaragoza (orcid)0000-0002-0136-5138 Mendez-Martinez, S. Universidad de Zaragoza (orcid)0000-0001-6072-1545 Martinez-Rincon, T. Subias, M. Polo, V. Universidad de Zaragoza (orcid)0000-0002-1402-3129 Ruberte, J. Ramirez, T. Vispe, E. (orcid)0000-0002-4921-4734 Luna, C. (orcid)0000-0003-2158-9777 Mayoral, J.A. Universidad de Zaragoza (orcid)0000-0003-1570-4257 Garcia-Martin, E. Universidad de Zaragoza (orcid)0000-0001-6258-2489 2013 765 Universidad de Zaragoza Dpto. Química Orgánica Área Química Orgánica 1013 646 Universidad de Zaragoza Dpto. Cirugía Área Oftalmología 1013 020 Universidad de Zaragoza Dpto. Cirugía Área Anatomía Patológica 8, 22 (2020), 6246-6260 Biomater. sci. Biomaterials science 2047-4830 441865 http://zaguan.unizar.es/record/107335/files/texto_completo.pdf Postprint 2556331 http://zaguan.unizar.es/record/107335/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:107335 articulos driver 2021-09-13-13:17:33 ARTICLE